Actively planning for HU6’s late-stage development in MASH - - HU6 is potential best-in-class oral MASH therapy designed to address unmet needs in MASH through a unique energy expenditure approach - ...

Approximately a third of the adult population worldwide has MASLD, the presence of steatosis (the accumulation of fat) in the ...

One of the best candidates for treatment of MASH recently has been a hormone called FGF21. There are three different FGF21 receptor types, and there have been several analogs of the hormone (with ...

Daix (France), Long Island City (New York, United States), March 18, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral ...

I am reversing my rating on Akero Therapeutics from Buy to Sell due to valuation concerns and a long-ish wait for pivotal data, and approval, if data supports it. Despite strong recent gains and ...

The Company will host a conference call and webcast, followed by a Q&A session, on Tuesday, March 19, 2024, at 8:00 am (New York), 1:00 pm (Paris). In order to participate to the conference call, ...

Imagine sitting in a doctor’s office and being told you have “non-alcoholic” liver disease. Before the doctor even finishes explaining what that means, your brain is already doing gymnastics trying to ...